Operating income
Flow – sum over the period · $M
Q1 FY2022
350$M
All values (43)
| Period | Value ($M) | Status |
|---|---|---|
| Q3 FY2026 | 445 | reported |
| Q2 FY2026 | 374 | reported |
| Q1 FY2026 | 283 | reported |
| Q4 FY2025 | 337 | derived |
| Q3 FY2025 | 403 | reported |
| Q2 FY2025 | 245 | reported |
| Q1 FY2025 | 197 | reported |
| Q4 FY2024 | 318 | derived |
| Q3 FY2024 | 261 | reported |
| Q2 FY2024 | 1,131 | reported |
| Q1 FY2024 | 303 | reported |
| Q4 FY2023 | 441 | derived |
| Q3 FY2023 | 375 | reported |
| Q2 FY2023 | 359 | reported |
| Q1 FY2023 | 362 | reported |
| Q4 FY2022 | 409 | derived |
| Q3 FY2022 | 321 | reported |
| Q2 FY2022 | 313 | reported |
| Q1 FY2022 | 350 | reported |
| Q4 FY2021 | 265 | derived |
| Q3 FY2021 | 240 | reported |
| Q2 FY2021 | 236 | reported |
| Q1 FY2021 | 314 | reported |
| Q4 FY2020 | 197 | derived |
| Q3 FY2020 | 59 | reported |
| Q2 FY2020 | 91 | reported |
| Q1 FY2020 | 153 | reported |
| Q4 FY2019 | 190 | derived |
| Q3 FY2019 | 141 | reported |
| Q2 FY2019 | 154 | reported |
| Q1 FY2019 | 217 | reported |
| Q4 FY2018 | 154 | derived |
| Q3 FY2018 | 113 | reported |
| Q2 FY2018 | 130 | reported |
| Q1 FY2018 | 146 | reported |
| Q4 FY2017 | 118 | derived |
| Q3 FY2017 | 43 | reported |
| Q2 FY2017 | 83 | reported |
| Q1 FY2017 | 166 | reported |
| Q4 FY2016 | 94 | derived |
| Q3 FY2016 | 60 | reported |
| Q2 FY2016 | 155 | reported |
| Q1 FY2016 | 215 | reported |
CSV with all sources · Technical ID: operating_income
More metrics for Jabil
Income statement
Balance sheet
Debt and interest
Revenue by segment/product/region
Operating income by segment
Sources & calculation
- Value
- $350M
- Period
- Q1 FY2022, ended Nov 30, 2021 · quarterly value (3 months, not cumulative)
- Source
- 10-Q, filed Jan 7, 2022 · 0001193125-22-004029
- Location
- us-gaap:OperatingIncomeLoss
- Confidence
- 1. – directly from an XBRL fact in the filing (or calculated exactly from it)
Versions
| v1 | $350M | Jan 7, 2022 | 10-Q 0001193125-22-004029 | reported · confidence 1. · current |